Arena Pharmaceuticals to Present at Two Upcoming Investor Conferences
SAN DIEGO, Sept. 18 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc.
(Nasdaq: ARNA) announced today that the company will be presenting at two
upcoming investor conferences during which it is scheduled to provide a
corporate overview of the company and its clinical development and discovery
programs. The conference information is as follows:
Oppenheimer 2nd Annual Diabetes Investor Conference
Presentation: Thursday, September 21, 2006 at 10:20 a.m. Eastern Time
(7:20 a.m. Pacific Time) at the Jolly Hotel-Madison Towers in New York
Presenting: Dominic P. Behan, Ph.D., Arena's Senior Vice President and
Chief Scientific Officer
2006 UBS Global Life Sciences Conference
Presentation: Monday, September 25, 2006 at 10:30 a.m. (7:30 a.m.
Pacific Time) at the Grand Hyatt in New York City
Presenting: Jack Lief, Arena's President and Chief Executive Officer
A live audio webcast of each presentation will be available under the
investor relations section of Arena's website at http://www.arenapharm.com.
Replays of the presentations will be available for 30 days following each
event. Please connect to Arena's website several minutes prior to the start of
the conference call to ensure adequate time for any software download that may
About Arena Pharmaceuticals
Arena is a clinical-stage biopharmaceutical company focused on
discovering, developing and commercializing oral drugs in four major
therapeutic areas: cardiovascular, central nervous system, inflammatory, and
metabolic diseases. Arena's most advanced product candidate, lorcaserin, is
being investigated in a Phase 3 clinical trial program for the treatment of
obesity. Arena's broad pipeline of novel compounds targeting G protein-coupled
receptors, an important class of validated drug targets, includes compounds
being evaluated for other serious diseases and disorders independently and
with our partners, Merck & Co., Inc. and Ortho-McNeil, Inc.
Arena Pharmaceuticals® and Arena® are registered service marks of the
company. CART is an unregistered service mark of the company. "APD" is an
abbreviation for Arena Pharmaceuticals Development.
Certain statements in this press release are forward-looking statements
that involve a number of risks and uncertainties. Such forward-looking
statements include statements about the expected phase 2 clinical trial of
APD125 and other statements about Arena's strategy and ability to develop
compounds and commercialize drugs. For such statements, Arena claims the
protection of the Private Securities Litigation Reform Act of 1995. Actual
events or results may differ materially from Arena's expectations. Factors
that could cause actual results to differ materially from the forward-looking
statements include, but are not limited to, Arena's planned clinical trials
and studies may not proceed at the time or in the manner Arena expects or at
all; the results of preclinical studies or clinical trials may not be
predictive of future results; the timing, success and cost of Arena's research
and development; Arena's ability to partner lorcaserin, APD125 or other of its
compounds or programs; Arena's ability to obtain additional financing; Arena's
ability to obtain and defend its patents; and the timing and receipt of
payments and fees, if any, from Arena's collaborators. Additional factors that
could cause actual results to differ materially from those stated or implied
by Arena's forward-looking statements are disclosed in Arena's filings with
the Securities and Exchange Commission. These forward-looking statements
represent Arena's judgment as of the time of this release. Arena disclaims any
intent or obligation to update these forward-looking statements, other than as
may be required under applicable law.
SOURCE Arena Pharmaceuticals, Inc.
CONTACT: Jack Lief, President and CEO, or David Walsey, Director,
Corporate Communications, both of Arena Pharmaceuticals, Inc.,
+1-858-453-7200, ext. 1682; or Carolyn Wang, Media Relations of WeissComm
Partners, +1-415-946-1065, for Arena Pharmaceuticals, Inc.
Web site: http://www.arenapharm.com